Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
High Growth Tech Stocks To Explore In November 2024

In This Article:

The United States market has experienced a notable upswing, climbing 3.9% over the last week and 33% over the past year, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

AsiaFIN Holdings

51.75%

58.17%

★★★★★★

Invivyd

47.87%

67.72%

★★★★★★

Sarepta Therapeutics

23.89%

42.65%

★★★★★★

TG Therapeutics

34.66%

56.48%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

Alnylam Pharmaceuticals

22.45%

70.66%

★★★★★★

Blueprint Medicines

25.26%

68.92%

★★★★★★

Travere Therapeutics

31.19%

72.58%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 240 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Vericel

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vericel Corporation is a commercial-stage biopharmaceutical company focused on the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America, with a market cap of $2.80 billion.

Operations: Vericel focuses on cellular therapies, generating revenue primarily from its biotechnology segment, which accounts for $226.84 million. The company's operations are centered in North America, targeting sports medicine and severe burn care markets.

Vericel's recent FDA approvals for MACI Arthro and pediatric NexoBrid signify strategic expansions in less invasive medical procedures and broader demographic reach, respectively. These innovations not only cater to a substantial segment of the $3 billion addressable market but also align with industry shifts towards specialized, patient-centric solutions. Financially, Vericel has demonstrated robust growth with a 21.3% increase in revenue year-over-year and is projecting continued expansion with revenue guidance set between $238 million to $242 million for 2024. This growth trajectory is underscored by an anticipated earnings increase of 51.6% annually over the next three years, reflecting both operational efficiency and market penetration.

NasdaqGM:VCEL Earnings and Revenue Growth as at Nov 2024
NasdaqGM:VCEL Earnings and Revenue Growth as at Nov 2024

AvePoint

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AvePoint, Inc. offers a cloud-native data management software platform across North America, Europe, the Middle East, Africa, and Asia Pacific with a market cap of $2.94 billion.


Waiting for permission
Allow microphone access to enable voice search

Try again.